Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gamma secretase inhibitor nirogacestat and secondary hidradenitis suppurativa: An expected on-target effect.

Annales de dermatologie et de venereologie·2026

Same author

Diabetic retinopathy screening telemedicine-based compared with standard of care : an economic analysis in a pilot experience of Italian healthcare.

Acta diabetologica·2025

Same author

Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real-Life Experience in the Lazio Region.

International journal of dermatology·2025

Same author

Eczematous reactions in patients with plaque psoriasis receiving biological therapy: an observational study.

European review for medical and pharmacological sciences·2024

Same author

Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Same author

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).

The Journal of dermatological treatment·2024

Search research articles

Related Experiment Video

Updated: May 20, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study.

C De Simone¹, A Maiorino, F Tassone

¹Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.

Journal of the European Academy of Dermatology and Venereology : JEADV

|July 14, 2012

Summary

Topical tacrolimus 0.1% ointment demonstrated significant efficacy in treating nail psoriasis, offering a promising therapeutic option for patients with limited treatment choices. Further research is recommended to confirm these findings.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Related Experiment Videos

Last Updated: May 20, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

Dermatology
Immunology

Background:

Nail psoriasis presents limited therapeutic options, especially when it is the sole manifestation of the disease.
Current treatments for nail psoriasis are insufficient for many patients.

Purpose of the Study:

To evaluate the efficacy and safety of topical tacrolimus 0.1% ointment for nail psoriasis.
To compare tacrolimus treatment against a no-treatment control in a randomized study.

Main Methods:

An open-label, randomized controlled study involving 21 psoriatic patients.
Tacrolimus 0.1% ointment was applied to affected nails on one hand for 12 weeks, with the other hand serving as a control.
Nail Psoriasis Severity Index (NAPSI) was used to assess disease severity.

Main Results:

A statistically significant improvement in nail psoriasis was observed in the tacrolimus-treated hands compared to control hands (P < 0.001).
The mean absolute change in NAPSI score was 13.0 for treated hands versus 3.0 for control hands.
One patient discontinued treatment due to acute paronychia.

Conclusions:

Tacrolimus 0.1% ointment shows potential as an effective and safe treatment for nail psoriasis.
Larger, double-blind studies are needed to validate these findings and confirm the safety profile.